SMARCB1 and bladder transitional cell carcinoma: In this study, we demonstrate that SMARCB1 deficiency, defined as the presence of deep or shallow SMARCB1 deletion and low SMARCB1 mRNA, may drive BLCA disease progression in approximately 32% of patients with BLCA.